Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis

Azuri, Joseph; Hammerman, Ariel; Aboalhasan, Enis; Sluckis, Ben; Arbel, Ronen

doi:10.1111/dom.14940

Cited by 25 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean estimated cost out-of-pocket for a 1 month supply of a GLP-1 agonist is $69.20 (SD $38.30) 112 . The cost per month without insurance for semaglutide or liraglutide can be as high as $1,200 to 1,300 113 . Obesity is a multifactorial issue that is influenced heavily by socioeconomic status 114 .…”

Section: Reviewmentioning

confidence: 99%

Glucagon-like Peptide-1 Agonists

Chan,

Mika,

Martin

et al. 2024

JBJS Reviews

View full text Add to dashboard Cite

» Orthopaedic surgeons are increasingly likely to encounter patients with obesity and/or type 2 diabetes taking glucagon-like peptide-1 (GLP-1) agonists for weight loss.» GLP-1 agonists are an effective treatment for weight loss with semaglutide and tirzepatide being the most effective agents. Randomized controlled trials using these agents have reported weight loss up to 21 kg (46 lb).» The use of GLP-1 agonists preoperatively can improve glycemic control, which can potentially reduce the risk of postoperative complications. However, multiple cases of intraoperative aspiration/regurgitation have been reported, potentially related to the effect of GLP-1 agonists on gastric emptying.» While efficacious, GLP-1 agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight. Multifactorial approaches to weight loss with focus on lifestyle modification in addition to GLP-1 agonists should be considered in such patients.» Although GLP-1 agonists are efficacious agents for weight loss, they may not be accessible or affordable for all patients. Each patient's unique circumstances should be considered when creating an ideal weight loss plan during optimization efforts.

show abstract

Section: Reviewmentioning

confidence: 99%

Glucagon-like Peptide-1 Agonists

Chan,

Mika,

Martin

et al. 2024

JBJS Reviews

View full text Add to dashboard Cite

show abstract

“…They both reduce blood glucose by stimulating insulin secretion and reducing glucagon secretion, both occurring in a glucose‐dependent manner. Regarding warnings and precautions, dulaglutide does not include the precaution of retinopathy, while the incidence of diabetic retinopathy was reported in the SUSTAIN 6 trial for semaglutide 41 . An indirect treatment comparison study showed that semaglutide 1.0 mg was significantly more effective than dulaglutide 3.0 mg and comparable with dulaglutide 4.5 mg in reducing body weight from baseline 51 .…”

Section: Clinical Trialsmentioning

confidence: 99%

Glucagon‐like peptide agonists: A prospective review

Mariam,

Niazi

2023

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

BackgroundGlucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as promising therapeutic options for addressing Type‐2 diabetes, obesity, and related conditions. Among these, semaglutide, tirzepatide, liraglutide etc., all notable GLP‐1RA, have gained attention owing to their favourable pharmacological properties and clinical efficacy.AimsThis comprehensive review aims to provide a detailed analysis of both the currently available GLP‐1RAs in the market and those undergoing clinical trials. The focus is on examining their mechanism of action, pharmacokinetics, efficacy in glycemic control and weight management, safety profile, and potential applications.Materials & MethodsThe review employs a systematic approach to gather information on GLP‐1RAs. Relevant literature from the currently literature and ongoing clinical trials is thoroughly examined. Detailed scrutiny is applied to understand the mechanism of action, pharmacokinetic properties, and clinical outcomes of these agents.ResultsThe review presents a comprehensive overview of the GLP‐1RAs, highlighting their distinct mechanisms of action, pharmacokinetic profiles, and clinical effectiveness in glycemic control and weight management. Safety profiles are also discussed, providing a holistic understanding of these therapeutic agents.DiscussionThe findings are discussed in the context of advancements in the field of GLP‐1RAs. Potential applications beyond diabetes and obesity are explored, shedding light on the broader implications of these agents in managing related conditions.ConclusionIn conclusion, this review underscores the significance of GLP‐1RAs, with a specific focus on semaglutide, in the management of type 2 diabetes, obesity, and beyond. By synthesizing information on their mechanisms, pharmacokinetics, efficacy, and safety, this review provides valuable insights into the potential benefits these agents offer, contributing to the ongoing discourse in the field.

show abstract

“…Although pharmacoeconomic studies evaluating the use of semaglutide or tirzepatide for weight loss are currently limited, Azuri et al 24 used published data from the STEP-1 and SURMOUNT-1 studies to determine the cost of treatment per 1% reduction in body weight. Using drug pricing information found on GoodRx, the authors listed the annual cost of semaglutide as $17,495 compared with $12,658 for tirzepatide as of October 2022.…”

Section: Pharmacoeconomicsmentioning

confidence: 99%

“…Cost comparison of semaglutide versus tirzepatide for obesity management. 24,25 Semaglutide Tirzepatide Estimated cost needed to treat for each 1% weight loss 25,26 $1845 $985…”

Section: Therapeutic Advancesmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity

Nguyen¹,

Wong²,

Cope³

2023

American Journal of Therapeutics

View full text Add to dashboard Cite

Background: Obesity is a major and growing public health concern. The associated cost for obesity and its related comorbidities is approximately 30% of US health care expenditures annually. As additional pharmacotherapeutic options join the market to combat obesity, it is important to understand the financial impact it may have on overall health care costs. This article explores the efficacy and pharmacoeconomics of incretin mimetics, semaglutide and tirzepatide, in the setting of obesity. Area of Uncertainty: The cost of incretin mimetics (semaglutide and tirzepatide) and its overall impact on obesity management within the health care arena is being explored. The cost comparison of these medications is to be determined; however, it may represent an added cost to the total US health care expenditures. Data Sources: A PubMed and Google Scholar search was conducted using various search terms (eg, semaglutide, tirzepatide, pharmacoeconomics, and obesity). Therapeutic Advances: Based on the data reviewed, both semaglutide and tirzepatide are effective medication options for obesity management. Obesity-related management expenditures exceed $173 billion for the US health care system annually. The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide was reported as $1845 and $985, respectively. More than 40% of adults (60 years or older) experience obesity. If 1%, 5%, or 10% of this population is treated with semaglutide, the annual Medicare costs will translate to excess of $2.6 billion, $13.3 billion, and $26.8 billion, respectively. Tirzepatide is not yet approved in the United States for obesity and its financial impact remains to be seen. Conclusions: Obesity is associated with burdensome health complications and costs. Semaglutide and tirzepatide are effective drug options for the management of obesity. The cost of these medications will no doubt present a challenge to the total health care expenditures, although the cost–benefit ratio may ultimately be favorable.

show abstract

Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis

Cited by 25 publications

References 21 publications

Glucagon-like Peptide-1 Agonists

Glucagon-like Peptide-1 Agonists

Glucagon‐like peptide agonists: A prospective review

Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity

Contact Info

Product

Resources

About